In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.
From vaccines to therapeutics, the emergence of mRNA as a versatile and potent biological tool across the healthcare landscape continues to demand new, innovative ways to scale mRNA manufacturing. To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results